[13] This area should be presented as exploratory and preclinical
When patients using semaglutide lose weight steadily, the mechanical pressure on joints decreases proportionally, often within weeks
For people interested in non-injectable options, sublingual semaglutide represents an emerging alternative, though the evidence base is less established than for injectable forms
One research letter published in JAMA Oncology last year, for example, suggests GLP-1 drugs might reduce the risk of colon cancer, even among people who are not overweight
These agents improve glycemic control, promote weight loss, lower blood pressure, and may reduce systemic inflammation and endothelial dysfunction [36,37,38,39]
I have lost 8 lbs on the starter dose this month